The fact that this relationship can be detected in TCGA‐PRAD tumor samples, expected to better represent the heterogeneity of each molecular subtype, strongly supports that the observed regulatory interaction between EGFR/STAT3 and ETV1 is likely to persist in vivo, independently of the tumor stage. This evidence concerns the gene EGFR and prostate adenocarcinoma.